Clinical Trial Update: A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II clinical trial of HYP-6589 as monotherapy and in combination with tyrosine kinase inhibitors for advanced non-small cell lung cancer with driver gene…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• HYP-6589

Snippet

Sponsor: Sichuan Huiyu Pharmaceutical Co., Ltd | Conditions: Solid Tumor | Phase 1, Phase 2 | Status: RECRUITING